DR-50102

N/A

Report date: 2026/03/19 17:01:23

Base Information

Drug NameDR-50102

Drug Alias NameDR-50102

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCarcinoembryonic antigen inhibitorsAnti-CD3

TargetsCarcinoembryonic antigen related cell adhesion molecule 5T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesZhejiang Doer Biologics Corp

China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Doer Biologics Corp

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A